logo

For the Inventor, By the Inventor

San Diego, CA, United States of America

Prometheus Biosciences, Inc.


USPTO Granted Patents = 15



Trademarks = 15

Forward Citations = 35

Loading Chart...
Loading Chart...

33 inventors (with patents filed for the assignee):

goldMedal Cindy T Dickerson (5 out of 5 patents)

silverMedal Janine Bilsborough (5 out of 7 patents)

bronzeMedal Jeffry Dean Watkins (5 out of 106 patents)

4.  Stephan R Targan (4 out of 53 patents)

5.  Robert Higuchi (3 out of 21 patents)

6.  Patricia McNeeley (3 out of 4 patents)

7.  Bradley Henkle (3 out of 4 patents)

8.  Dalin Li (3 out of 13 patents)

9.  Laurens Kruidenier (3 out of 3 patents)

10.  Mahyar Sabripour (3 out of 3 patents)

11.  Dermot P Mcgovern (3 out of 10 patents)

12.  Sharat Singh (2 out of 100 patents)

13.  Janine M Bilsborough (2 out of 55 patents)

14.  Rafael Rojas (2 out of 2 patents)

15.  Matthew Reissman (2 out of 2 patents)


15 patents:

1. 12741968 - Therapeutic agents targeting GPR35 (2026-09-22),
2. 12391752 - Methods of enriching or amplifying nucleic acids in a sample from a patient with inflammatory bowel disease (2025-08-19),
3. 12305236 - Methods and systems for selection and treatment of patients with inflammatory diseases (2025-05-20),
4. 12215147 - Methods of selecting, based on polymorphisms, an inflammatory bowel disease subject for treatment with an anti-TL1A antibody (2025-02-04),
5. 11999789 - Humanized antibodies to TNF-like ligand 1A (TL1A) and uses thereof (2024-06-04),
6. 11866505 - Anti-CD30L antibodies and uses thereof (2024-01-09),
7. 11773101 - GPR35 modulators (2023-10-03),
8. 11440954 - Optimized anti-TL1A antibodies (2022-09-13),
9. 11292848 - Humanized antibodies to TNF-like ligand 1A (TL1A) and uses thereof (2022-04-05),
10. 11162943 - Methods for assessing mucosal healing in Crohn's disease patients (2021-11-02),
11. 11136386 - Methods of treating Crohn's disease or ulcerative colitis by administering inhibitors of tumor necrosis factor-like cytokine 1A (TL1A) (2021-10-05),
12. 11053251 - GPR35 modulators (2021-07-06),
13. 10794906 - Assays for detecting neutralizing autoantibodies to biologic therapy (2020-10-06),
14. 10697961 - Methods for predicting post-operative recurrence of Crohn's disease (2020-06-30),
15. 10689439 - Optimized anti-TL1A antibodies (2020-06-23),
Company Overview
Prometheus Biosciences, Inc. is a biotechnology company based in San Diego, California, specializing in the development of innovative therapeutics for autoimmune diseases. The company focuses on advancing precision medicine through its proprietary platform, which integrates advanced genomic and proteomic technologies. Prometheus aims to transform the treatment landscape for patients suffering from conditions such as inflammatory bowel disease by leveraging its expertise in biomarker discovery and drug development.
Profile summary synthesized from public USPTO records and patent filings.

logo

Company Badge

USPTO Data Jan 1 1976 - Oct 13 2026

Prometheus Biosciences, Inc. USPTO Patent Assignee Logo
15 Patents

#375 in San Diego, CA

#5,027 in California

#21,052 in US

#39,921 in the World

San Diego, CA (US)
San Diego, CA, United States of America

Prometheus Biosciences, Inc.

Forward Citations = 35

33 inventors:

goldMedal Cindy T Dickerson (5 out of 5 patents)

silverMedal Janine Bilsborough (5 out of 7 patents)

bronzeMedal Jeffry Dean Watkins (5 out of 106 patents)

4.  Stephan R Targan (4 out of 53 patents)

5.  Robert Higuchi (3 out of 21 patents)

IDiyas Innovation Intelligence. (2026). Company Patent Portfolio: Prometheus Biosciences, Inc.. Retrieved from https://idiyas.com/company/prometheus-biosciences

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…